Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

Supporting evidence

• Evaluation report

• Partial review: draft guidance consultation committee papers (PDF 3.39 MB)

  Published:

  13 March 2024

• Partial review: final draft guidance committee papers 1 (PDF 2 MB)

  Published:

  13 March 2024

• Partial review: final draft guidance committee papers 2 (PDF 931 KB)

  Published:

  13 March 2024

• Draft guidance consultation committee papers (PDF 15.33 MB)

  Published:

  29 March 2023

• Final draft guidance committee papers (PDF 10.21 MB)

  Published:

  29 March 2023